David Lebowitz Citigroup Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
25
Avg Return
Past Year
Past Year
29%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
65.4%
Neutral
30.8%
Negative
3.8%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
Health Information Services
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Buy
Maintained
| $84 |
10%
upside
| 3 | +34% |
0
%
| 3 Sep ‘25 4 months ago |
|
|
|
Buy
Maintained
| $84 |
34%
upside
| 4 | +14% |
0
%
| 2 Sep ‘25 4 months ago |
|
|
|
Buy
Maintained
| $48 |
87%
upside
| 1 | +6.8% |
0
%
| 20 Aug ‘25 5 months ago |
|
|
|
Neutral
Downgraded
| $20 |
19%
upside
| 1 | – |
–
| 15 Aug ‘25 5 months ago |
|
|
|
Buy
Maintained
| $290 |
41%
upside
| 2 | +8% |
0
%
| 8 Aug ‘25 5 months ago |
|
|
|
Buy
Maintained
| $103 |
3%
downside
| 2 | +25% |
0
%
| 30 Jul ‘25 5 months ago |
|
|
|
Neutral
Maintained
| $38 |
12%
upside
| 2 | – |
–
| 24 Jul ‘25 5 months ago |
|
|
|
Buy
Maintained
| $22 |
44%
downside
| 1 | +219% |
0
%
| 18 Jul ‘25 6 months ago |
|
|
|
Buy
Maintained
| $67 |
12%
downside
| 2 | +45% |
0
%
| 11 Jul ‘25 6 months ago |
|
|
|
Neutral
Upgraded
| $129 |
0%
downside
| 1 | – |
–
| 4 Jun ‘25 7 months ago |
|
|
|
Buy
Maintained
| $56 |
27%
upside
| 2 | +17% |
0
%
| 15 May ‘25 8 months ago |
|
|
|
Neutral
Maintained
| $10 |
20%
downside
| 2 | – |
–
| 9 May ‘25 8 months ago |
|
|
|
Neutral
Maintained
| $1.50 |
16%
upside
| 2 | – |
–
| 4 Mar ‘25 10 months ago |
|
|
|
Sell
Maintained
| $45 |
38%
downside
| 1 | -49% |
0
%
| 12 Feb ‘25 11 months ago |
|